{
    "root": "4cfcfc8e-9641-40c5-be4f-85581d88cac4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Flucytosine",
    "value": "20250326",
    "ingredients": [
        {
            "name": "FLUCYTOSINE",
            "code": "D83282DT06"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        }
    ],
    "indications": "flucytosine capsules usp indicated treatment serious infections caused susceptible strains candida and/or cryptococcus . candida : septicemia , endocarditis urinary system infections effectively treated flucytosine . limited trials pulmonary infections justify flucytosine . cryptococcus : meningitis pulmonary infections treated effectively . septicemias urinary tract infections limited , good responses reported . flucytosine capsules usp used combination amphotericin b treatment systemic candidiasis cryptococcosis emergence resistance flucytosine capsules usp ( microbiology ) .",
    "contraindications": "usual flucytosine capsules usp 50 150 mg/kg/day administered divided doses 6-hour intervals . nausea vomiting may reduced avoided capsules given time 15-minute period . bun serum creatinine elevated , signs renal impairment , initial dose lower level ( ) . flucytosine capsules usp used combination amphotericin b treatment systemic candidiasis cryptococcosis emergence resistance flucytosine capsules usp ( microbiology ) .",
    "warningsAndPrecautions": "flucytosine capsules usp , 250 mg size 2 hard gelatin capsule blue opaque cap grey opaque body imprinted `` nl 771 `` cap black ink `` 250 `` body red ink filled white white powder . cartons 30 capsules ( 6 capsules blister pack x 5 ) , ndc 0904-6834-07 flucytosine capsules usp , 500 mg size 0 hard gelatin capsule grey opaque cap white opaque body imprinted `` nl 770 `` cap black ink `` 500 `` body red ink , filled white white powder . cartons 30 capsules ( 6 capsules blister pack x 5 ) , ndc 0904-6835-07 store 25°c ( 77°f ) ; excursions permitted 15°c - 30°c ( 59°f - 86°f ) . manufactured : novel laboratories , inc. somerset , nj 08873 manufactured : lupin pharmaceuticals , inc. baltimore , md 21202 packaged distributed : major® pharmaceuticals indianapolis , 46268 usa refer package label distributor 's ndc number sap code : 270545 rev : 05/2022",
    "adverseReactions": "flucytosine capsules , usp contraindicated patients known hypersensitivity . flucytosine capsules , usp contraindicated patients known complete dihydropyrimidine dehydrogenase ( dpd ) enzyme deficiency ( ) .",
    "indications_original": "Flucytosine Capsules USP is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.\n                  \n                     Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine.\n                  \n                     Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported.\n                  Flucytosine Capsules USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules USP (See MICROBIOLOGY).",
    "contraindications_original": "The usual dosage of Flucytosine Capsules USP is 50 to 150 mg/kg/day administered in divided doses at 6-hour intervals. Nausea or vomiting may be reduced or avoided if the capsules are given a few at a time over a 15-minute period. If the BUN or the serum creatinine is elevated, or if there are other signs of renal impairment, the initial dose should be at the lower level (see WARNINGS).\n                  Flucytosine Capsules USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules USP (See MICROBIOLOGY).",
    "warningsAndPrecautions_original": "Flucytosine Capsules USP, 250 mg are size 2 hard gelatin capsule with blue opaque cap and grey opaque body imprinted with \"NL 771\" on the cap with black ink and \"250\" on the body with red ink filled with white to off white powder.\n                  Cartons of 30 capsules (6 capsules each blister pack x 5), NDC 0904-6834-07\n                  Flucytosine Capsules USP, 500 mg are size 0 hard gelatin capsule with grey opaque cap and white opaque body imprinted \"NL 770\" on the cap with black ink and \"500\" on the body with red ink, filled with white to off white powder.\n                  Cartons of 30 capsules (6 capsules each blister pack x 5), NDC 0904-6835-07\n                  Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F - 86°F).\n                  Manufactured by:\n                  \n                     Novel Laboratories, Inc.\n                  \n                  Somerset, NJ 08873\n                  Manufactured for:\n                  \n                     Lupin Pharmaceuticals, Inc.\n                  \n                  Baltimore, MD 21202\n                  \n                     Packaged and Distributed by:\n                  \n                  \n                     MAJOR® PHARMACEUTICALS\n                  \n                  Indianapolis, IN 46268 USA\n                  Refer to package label for Distributor's NDC Number\n                  SAP code: 270545\n                  Rev: 05/2022",
    "adverseReactions_original": "Flucytosine Capsules, USP is contraindicated in patients with a known hypersensitivity to the drug.\n                  Flucytosine Capsules, USP is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency (see WARNINGS)."
}